Abstract | BACKGROUND: METHODS AND RESULTS: Our study cohort included 320 consecutive STEMI patients undergoing PPCI with HTB who were randomly assigned to receive either TA before PPCI (TA group, n = 160) or PPCI alone (standard PPCI group, n = 160). The baseline characteristics of study participants were well-matched. After 30 ± 2 days, serum Lp-PLA2 levels decreased by 53.9% in the TA group (152.9 ± 58.1 ng/mL) and decreased by 31.2% in the standard PPCI group (84.2 ± 86.6 ng/mL, p < 0.001). The TA group had a significantly lower prevalence of balloon predilatation, number of stents used, total stent length and corrected thrombolysis in myocardial infarction frame count, and a higher percentage of myocardial blush grade ≥ 2 compared with the standard PPCI group (all p < 0.001). No significant difference between the groups was observed in 30 ± 2 days for major adverse cardiovascular and cerebrovascular events (p = 0.702). CONCLUSIONS: After 30 ± 2 days of treatment, TA may significantly reduce serum levels of Lp-PLA2 in STEMI patients undergoing PPCI with HTB.
|
Authors | Bao-Feng Chen, Yun Deng, Xin Xu, Shao-Chun Ma, Liang-Qiu Tang, Jin-Feng Chen, Wei-Qian Sun, Su-Fang Liu, Jia-Rong Liang |
Journal | Acta Cardiologica Sinica
(Acta Cardiol Sin)
Vol. 34
Issue 3
Pg. 233-241
(May 2018)
ISSN: 1011-6842 [Print] China (Republic : 1949- ) |
PMID | 29844644
(Publication Type: Journal Article)
|